期刊文献+

脂联素对高糖环境下大鼠肾小管上皮细胞血管内皮生长因子表达的影响 被引量:1

Effect of adiponectin on the expression of VEGF in NRK-52E cells induced by high glucose
下载PDF
导出
摘要 目的探讨脂联素(adiponectin,ADPN)对高糖环境下大鼠肾小管上皮细胞(NRK-52E)血管内皮生长因子(vascular endothelialgrowthfactor,VEGF)表达的影响。方法用含不同浓度葡萄糖的DMEM培养基体外培养NRK-52E细胞,随机分6组(每组5个样本,重复5次):A组,含5.5mmol/L葡萄糖培养基对照组;B组,含5.5mmol/L葡萄糖+甘露醇19.5mmol/L培养基组;C组,含25mmol/L葡萄糖培养基组;D组,含25mmol/L葡萄糖培养基+脂联素1mg/L组:E组,含25mmol/L葡萄糖培养基+脂联素2.5mg/L组;F组,含25mmol/L葡萄糖培养基+脂联素5mc/L组,培养24h。以逆转录一聚合酶链反应(RT-PCR)检测VEGF的表达,免疫荧光检测不同浓度干预组VEGF蛋白的表达影响。结果A组细胞VEGFmRNA表达量为(0.367±0.028);B组为(0.346±0.045),与A组比较无统计学差异(P〉0.05);C组为(0.692±0.053),显著高于A组(P〈0.01);D组为(0.562±0.049),低于C组(P〈0.05)。E组为(0.381±0.035),与A组相近,但无统计学差异(P〉0.05);F组为(0.295±0.031),低于A组(P〈0.01)。不同浓度脂联素各组间比较,有统计学差异(P〈0.05)。免疫荧光检测VEGF表达情况;B组与A组无差异;C组显著高于A组(P〈0.01);D组低于C组(P〈0.05)。E组与A组相近,但无统计学差异(P〉0.05);F组低于A组(P〈0.05)。不同浓度脂联素各组间比较有统计学差异(P〈0.05)。结论ADPN能通过减少肾小管上皮细胞VEGF的表达对肾小管间质起保护作用。 Objective To investigate the effect of adiponeetin (ADPN) on the expression of vascular endothelial growth factor (VEGF) induced by high glucose in kidney tubular epithelial cells (NRK-52E) of rats. Methods The NRK-52E cells were cultured with DMEM medium with different concentrations of glucose for 24 h in vitro in 6 groups (five samples in each group, and the experiment was repeated for 5 times) .. group A (DMEM medium with 5.5 mmol/L of glucose as control group) group B (DMEM medium with 5.5 mmol/L of glucose and 19. 5 mmol/L mannitol) group C (DMEM medium with 25 mmol/L of glucose), group D (DMEM medium with 25 mmol/L of glucose medium and 1 mg/L of recombinant adiponeetin) ; group E (DMEM medium with 25 mmol/L of glucose medi- um and 2. 5 mg/L of recombinant adiponectin) ; group F (DMEM medium with 25 mmol/L of glucose medium and 5 mg/L of recombinant adiponectin). The VEGF mRNA was evaluated by RT-PCR and the cellular VEGF was detected by immunofluorescence after 24 h. Results The expression of VEGF mRNA in groups A and B was (0. 367 ± 0. 028) and (0. 346 ±0. 045) respectively (P〈0. 05) ; (0. 692 ± 0. 053) in group C, significantly higher than that in group A (P〈0. 01) ; (0. 562 ± 0. 049) in group D, significantly lower than that in group C (P〈0. 05) ; no significant difference between group E and group A (P〈0. 05); (0. 295 ±0. 031) in group F, significantly lower than that in group A (P〈0. 05). There was statistically significant difference bettween different groups of different concentra tions of recombinant adiponectin (P〈0. 05). The results of immunofluorescence revealed that there was no significant difference in the expression of VEGF between group B and group A. It was significantly higher in group C than in group A (P〈0. 01), and that in group D was significantly higher than in group C (P〈0. 05), and there was no significant difference between group E and group A (P〉 0. 05). The expression of VEGF in group F was significantly lower than in group A (P〈0. 05). There was statistically significant difference bettween different groups of different concentrations of recombi nant adiponectin (P〈0. 05). Conclusions ADPN plays a protective role through the alleviation of VEGF expression in renal tubules.
出处 《临床肾脏病杂志》 2014年第4期235-238,共4页 Journal Of Clinical Nephrology
基金 2012年武汉市科技攻关项目(NO.201260523173-6)
关键词 高糖 大鼠肾小管上皮细胞 脂联素 血管内皮生长因子 High glucose Rat renal tubular epithelial cells Adiponectin Vascular endothelial growth factor
  • 相关文献

参考文献15

  • 1Yilmaz MI, Saglam M, Qureshi AR, et al. Endothelial dysfunc- tion in type-2 diabetics with early diabetic nephropathy is asso ciated with low circulating adiponectin. Nephrol Dial Trans- plant,2008,23:1621 -1627.
  • 2Fang Y,Yu X, Liu Y, et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF al- pha activation. Am J Physiol Renal Physiol, 2013,304: F1274- F1282.
  • 3Yamamoto Y,Maeshima Y,Kitayama H, et al. Tumstatin pep tide,an inhibitor of Angiogenesis, prevents glomerular hyper- trophy in the early stage of diabetic nephropathy. Diabetes, 2004,53: 1831-1840.
  • 4Kang DH,Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nepbrol, 2002,3 : 806-816.
  • 5Schrijvers BF, Flyvbjerg A, Vriese AS. The role of vascular en dothelial growth factor (VEGF) in renal pathology. Kidney Int, 2004,65 : 2003-2017.
  • 6Eremina V, Cui S, Gerber H, et al. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol, 2006,17: 724-735.
  • 7Ha C, Hsu YC, Tseng CC, et al. Simvastatin alleviates diabe- tes-induced VEGFmediated nephropathy via the modulation of Ras signaling pathway. Renal Failure, 2008,30 : 557-565.
  • 8Ma YY, Sun D, Yin ZC. Transplantation of endothelial progeni- tor cells alleviates renal interstitial fibrosis in a mouse model of ureteral obstruction 2010.
  • 9Advani A, Connelly KA, Advani N., et aL Role of the eNOS- NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes. Blamed Res Int, 2013,2013: 201475.
  • 10Wendt TM, Tanji N, Guo J, et al. RAGE drives the develop- ment of glomernlosclerosis and implicates podoeyte activation in the pathogenesis of diabetic nephropathy. American Journal of Patbology, 2003,162: 1123-1137.

二级参考文献22

  • 1Santilli F,Spagnoli A,Mohn A,et al.Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria[J].J Clin Endocrinol Metab,2001;86(8):3871-6.
  • 2Gable DR,Matin J,Whittall R,et al.Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects[J].Ann Hum Genet,2007;71(Pt 4):453-66.
  • 3von Eynatten M,Liu D,Hock C,et al.Urinary adiponectin excretion:a novel marker for vascular damage in type 2 diabetes[J].Diabetes,2009;58(9):2093-9.
  • 4Funatsu H,Yamashita H,Nakamura S,et al.Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema[J].Ophthalmology,2006;113(2):294-301.
  • 5Flyvbjerg A,Dagnaes-Hansen F,de Vriese AS,et al.Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody[J].Diabetes,2002;51(10):3090-4.
  • 6Sasso FC,Torella D,Carbonara O,et al.Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease[J].J Am Coll Cardiol,2005;46(5):827-34.
  • 7Mahadev K,Wu X,Donnelly S,et al.Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells[J].Cardiovasc Res,2008;78(2):376-84.
  • 8Tan KC,Xu A,Chow WS,et al.Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation.J Clin Endocrinol Metab,2004,89:765-769.
  • 9Maeda N,Funahashi T.Adiponectin knockout mice.Nippon Rinsho,2004,62:1067-1076.
  • 10Kadowaki T,Yamauchi T.Adiponectin and adiponectin receptors.Endocr Rev,2005,26:439-451.

共引文献12

同被引文献11

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部